Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Givlaari™ (givosiran) for the Treatment of Acute Hepatic Porphyria

Drug Name

Givlaari™ (givosiran)

Developer

Alnylam Pharmaceuticals

Therapy Class

RNA interference (RNAi) therapy

Product Description

Aminolevulinic acid synthase 1-directed small RNAi

Current Indication

Acute hepatic porphyria

Market Sector

Genetics

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top